Evolus, Inc. (EOLS)
NASDAQ:EOLS
Want to see EOLS full AI Analyst Report?
EOLS Stock Chart & Stats
$4.69
-$0.47(-4.38%)
At close: 4:00 PM EST
$4.69
-$0.47(-4.38%)
Day’s Range― - ―
52-Week Range$3.86 - $11.42
Previous CloseN/A
Volume344.54K
Average Volume (3M)816.47K
Market Cap
$420.81M
Enterprise Value$535.92M
Total Cash (Recent Filing)$53.83M
Total Debt (Recent Filing)$155.00M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Aug 05, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding65,854,750
10 Day Avg. Volume612,019
30 Day Avg. Volume816,474
Financial Highlights & Ratios
PEG Ratio6.72
Price to Book (P/B)-18.55
Price to Sales (P/S)1.44
P/FCF Ratio-9.38
Enterprise Value/Market Cap1.27
Enterprise Value/Revenue1.80
Enterprise Value/Gross Profit2.74
Enterprise Value/Ebitda-19.39
Forecast
1Y Price Target
$14.50Price Target Upside209.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.09
Revenue Forecast (FY)$330.05M
Bulls Say, Bears Say
Bulls Say
International GrowthToxin product gains market share both domestically and internationally while sales outside the United States are becoming a meaningful portion of revenue, supporting revenue diversification and growth.
Product LaunchesLaunch of Evolysse fillers and plans for a broader European product rollout expand the portfolio and have driven a sales pickup, enhancing the company's ability to compete with category leaders.
Profitability And Commercial ProgramsCompany reached profitability and new commercial initiatives such as growth rebates, co-branded marketing, and volume-based pricing drive larger purchases, stronger account retention, and potential margin stability.
Bears Say
Financing Terms RiskAccess to additional debt facilities improves liquidity but the asset-backed revolver's minimum utilization requirement and relatively high interest terms raise financing costs and operational risk.
Guidance And Market SizingManagement's recalibration of long-term outlook and rebased market assumptions indicate a smaller addressable market and slower growth, increasing downside risk to revenue expectations.
Limited New Information And Analyst CautionCompany updates added little beyond prior disclosures and an analyst maintained a Hold while seeking clearer visibility, reducing the likelihood of near-term positive stock movement.
Evolus News
EOLS FAQ
What was Evolus, Inc.’s price range in the past 12 months?
Evolus, Inc. lowest stock price was $3.86 and its highest was $11.42 in the past 12 months.
What is Evolus, Inc.’s market cap?
Evolus, Inc.’s market cap is $420.81M.
When is Evolus, Inc.’s upcoming earnings report date?
Evolus, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 89 days.
How were Evolus, Inc.’s earnings last quarter?
Evolus, Inc. released its earnings results on May 04, 2026. The company reported -$0.046 earnings per share for the quarter, beating the consensus estimate of -$0.113 by $0.067.
Is Evolus, Inc. overvalued?
According to Wall Street analysts Evolus, Inc.’s price is currently Undervalued.
Does Evolus, Inc. pay dividends?
Evolus, Inc. does not currently pay dividends.
What is Evolus, Inc.’s EPS estimate?
Evolus, Inc.’s EPS estimate is -0.04.
How many shares outstanding does Evolus, Inc. have?
Evolus, Inc. has 65,854,750 shares outstanding.
What happened to Evolus, Inc.’s price movement after its last earnings report?
Evolus, Inc. reported an EPS of -$0.046 in its last earnings report, beating expectations of -$0.113. Following the earnings report the stock price went up 14.158%.
Which hedge fund is a major shareholder of Evolus, Inc.?
Currently, no hedge funds are holding shares in EOLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evolus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.50 (209.17% Upside)
$14.50 (209.17% Upside)
Blogger Sentiment
Bullish
EOLS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 424.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.5%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.53%
12-Months-Change
Fundamentals
Return on Equity
174.92%
Trailing 12-Months
Asset Growth
3.41%
Trailing 12-Months
Company Description
Evolus, Inc.
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
EOLS Company Deck
EOLS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly constructive picture: revenue growth (Q1 +7%), healthy margins (adjusted gross margin 68%), expanding commercial footprint and loyalty (Rewards members +27% YoY), and a return to positive adjusted EBITDA ($0.6M) alongside reiterated full-year guidance and planned product launches (Esteem in Europe, Sculp FDA in Q4). Key risks include timing/seasonality comparatives, a newly announced 15% South Korea tariff on certain products, a still-small contribution from Evolisse amid a soft filler market, and continued competitive entrants. On balance, the operational improvements, profitability momentum, and clear pipeline/launch cadence outweigh the cited headwinds.View all EOLS earnings summariesEOLS Stock 12 Month Forecast
Average Price Target
$14.50
▲(209.17% Upside)
Technical Analysis
Emergent Biosolutions
―
Rockwell Med
―
Organogenesis Holdings
―
Aquestive Therapeutics
―
Journey Medical Corp
―
Ownership Overview
3.39% Insiders
7.89% Mutual Funds
2.95% Other Institutional Investors
75.16% Public Companies and
Individual Investors